Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 10/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.73 |
| ▸ | HTR2A | P28223 | 2/20 | 0.73 |
| ▸ | HTR2C | P28335 | 2/20 | 0.73 |
| ▸ | HRH1 | P35367 | 2/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.73 |
| ▸ | DRD3 | P35462 | 2/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.73 |
| ▸ | HTR2B | P41595 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nisoxetine SCHEMBL30026153 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL29401038 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL3897550 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL3892886 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL29440249 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL467262 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL14973458 | 0.97 | SLC6A4 (0.94) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL4083146 | 0.93 | SLC6A4 (0.86) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| [3H]Nisoxetine SCHEMBL29463855 | 0.90 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL5309993 | 0.86 | SLC6A2 (0.76) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2534 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-03-26 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260027070-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-01-29 | — | — | US | claimed |
| US-20250325510-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APRIMED INC DELAWARE (US) | 2025-10-23 | — | — | US | claimed |
| EP-4635514-A2 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | The Brigham & Women's Hospital, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250186371-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2025-06-12 | — | — | US | claimed |
| US-20250114321-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2025-04-10 | — | — | US | claimed |
| CN-119789855-A | Methods and compositions for treating sleep apnea | 爱普宁公司(特拉华) | 2025-04-08 | — | — | CN | claimed |
| US-20030130355-A1 | Therapeutic agents | KNOLL GMBH (DE) | 2003-07-10 | — | — | US | claimed |
| EP-1308435-A2 | Process for producing optically active amino alcohols | Kanto Kagaku Kabushiki Kaisha (JP) | 2003-05-07 | — | — | EP | claimed |
| EP-0831799-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMA INC (US) | 2003-05-02 | — | — | EP | claimed |
| EP-1259292-A2 | THERAPEUTIC AGENTS | Knoll GmbH (DE) | 2002-11-27 | — | — | EP | claimed |
| US-20020161002-A1 | Norepinephrine reuptake inhibitors; to increase memory function such as long-term memory and recall ability | SENTION, INC. | 2002-10-31 | — | — | US | claimed |
| WO-2002053104-A2 | USE OF CATECHOLAMINE REUPTAKE INHIBITORS TO ENHANCE MEMORY | SENTION, INC. (US) | 2002-07-11 | — | — | WO | claimed |
| WO-2002043652-A2 | ANTI-PROLIFERATIVE DRUGS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2002-06-06 | — | — | WO | claimed |
| WO-2001062341-A2 | COMBINATION PRODUCT FOR THE TREATMENT OF OBESITY | KNOLL GMBH (DE) | 2001-08-30 | — | — | WO | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |